Prognostic value of regional myocardial flow reserve derived from
Coronary artery disease
Myocardial blood flow
Myocardial flow reserve
Positron emission tomography
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
30
12
2020
accepted:
09
06
2021
pubmed:
1
7
2021
medline:
3
2
2022
entrez:
30
6
2021
Statut:
ppublish
Résumé
To assess the prognostic value of regional quantitative myocardial flow measures as assessed by We retrospectively included 150 consecutive patients with suspected CAD who underwent clinically indicated 13 N-ammonia PET-MPI and who did not undergo revascularization within 90 days of PET-MPI. The presence or absence of a decreased global myocardial flow reserve (i.e., MFR < 2) as well as decreased regional MFR (i.e., ≥ 2 adjacent segments with MFR < 2) was recorded, and patients were classified as having preserved global and regional MFR (MFR group 1), preserved global but decreased regional MFR (MFR group 2), or decreased global and regional MFR (MFR group 3). We obtained follow-up regarding major adverse cardiac events (MACE, i.e., a combined endpoint including all-cause death, non-fatal myocardial infarction, and late revascularization) and all-cause death. Over a median follow-up of 50 months (IQR 38-103), 30 events occurred in 29 patients. Kaplan-Meier analysis showed significantly reduced event-free and overall survival in MFR groups 2 and 3 compared to MFR group 1 (log-rank: p = 0.015 and p = 0.013). In a multivariable Cox regression analysis, decreased regional MFR was an independent predictor for MACE (adjusted HR 3.44, 95% CI 1.17-10.11, p = 0.024) and all-cause death (adjusted HR 4.72, 95% CI 1.07-20.7, p = 0.04). A decreased regional MFR as assessed by 13 N-ammonia PET-MPI confers prognostic value by identifying patients at increased risk for future adverse cardiac outcomes and all-cause death.
Identifiants
pubmed: 34191100
doi: 10.1007/s00259-021-05459-0
pii: 10.1007/s00259-021-05459-0
pmc: PMC8712296
doi:
Substances chimiques
Ammonia
7664-41-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
311-320Informations de copyright
© 2021. The Author(s).
Références
J Nucl Cardiol. 2006 Nov;13(6):e121-51
pubmed: 17174789
J Nucl Cardiol. 2021 Feb;28(1):263-273
pubmed: 30895563
J Am Coll Cardiol. 2014 Apr 1;63(12):1145-1155
pubmed: 24486266
J Am Coll Cardiol. 2011 Aug 9;58(7):740-8
pubmed: 21816311
Circulation. 1994 Mar;89(3):1013-22
pubmed: 8124786
J Nucl Cardiol. 2019 Apr;26(2):561-568
pubmed: 28685251
Circulation. 1998 Feb 17;97(6):535-43
pubmed: 9494023
Eur Heart J Cardiovasc Imaging. 2013 Dec;14(12):1203-10
pubmed: 23660750
J Nucl Med. 2011 May;52(5):726-32
pubmed: 21498538
J Clin Invest. 1987 May;79(5):1473-8
pubmed: 3494749
Circulation. 1993 Apr;87(4):1354-67
pubmed: 8462157
Eur Heart J Cardiovasc Imaging. 2020 Jul 1;21(7):777-786
pubmed: 31620792
Circulation. 2014 Apr 8;129(14):1493-501
pubmed: 24573351
J Am Coll Cardiol. 1986 Jan;7(1):103-13
pubmed: 3941196
J Am Coll Cardiol. 2009 Jul 7;54(2):150-6
pubmed: 19573732
J Nucl Cardiol. 2018 Feb;25(1):269-297
pubmed: 29243073
JACC Cardiovasc Imaging. 2021 Feb;14(2):454-464
pubmed: 32771569
J Nucl Med. 2019 Mar;60(3):410-417
pubmed: 30115688
J Nucl Cardiol. 1996 Nov-Dec;3(6 Pt 1):494-507
pubmed: 8989674
Circulation. 2017 Dec 12;136(24):2325-2336
pubmed: 28864442
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
EuroIntervention. 2018 Feb 20;13(14):1696-1704
pubmed: 28649949
J Nucl Cardiol. 2017 Dec;24(6):2064-2128
pubmed: 28916938
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2290-2298
pubmed: 28815291
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1434-1444
pubmed: 33174090
J Am Coll Cardiol. 2018 Nov 27;72(21):2625-2641
pubmed: 30466521